Genetically Engineered Autologous Cells for Antiangiogenic Therapy of Breast Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Genetically Engineered Autologous Cells for Antiangiogenic Therapy of Breast Cancer PDF full book. Access full book title Genetically Engineered Autologous Cells for Antiangiogenic Therapy of Breast Cancer by . Download full books in PDF and EPUB format.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 52
Get Book Here
Book Description
Cancer growth and spread depends on the orchestrated proliferation of tumor-associated blood supply. Cancer cells release signals that instruct the body to build new blood vessels, angiogenesis, required to feed the tumor as it increases in size. Pharmacological agents, i.e. proteins and derivatives, that interfere with angiogenesis, in cancer bearing mice, stop cancer growth and lead to its regression. Animal modeling has revealed that repeated administration of large amounts of such antiangiogenic proteins is required for anti- cancer effect. This may be logistically difficult to achieve in larger beings such as humans. A remedy to this problem would involve a combined cell and gene therapy approach. We propose that normal tissue such as marrow stromal cells (MSCs) can be harvested from patients, genetically engineered, and subsequently returned to the patient as an implant releasing on a continuous basis therapeutic proteins that interfere with cancer growth and spread. We have already developed and published most of the key components required to develop this novel therapeutic modality, such as vectors, MSCs, and matrices. Also thus far, we have shown significant decrease in tumor progression over time with Interleukin-l2-secreting MSCs in the 4T1 mouse model of breast cancer and ascertained reproducibility of these results.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 52
Get Book Here
Book Description
Cancer growth and spread depends on the orchestrated proliferation of tumor-associated blood supply. Cancer cells release signals that instruct the body to build new blood vessels, angiogenesis, required to feed the tumor as it increases in size. Pharmacological agents, i.e. proteins and derivatives, that interfere with angiogenesis, in cancer bearing mice, stop cancer growth and lead to its regression. Animal modeling has revealed that repeated administration of large amounts of such antiangiogenic proteins is required for anti- cancer effect. This may be logistically difficult to achieve in larger beings such as humans. A remedy to this problem would involve a combined cell and gene therapy approach. We propose that normal tissue such as marrow stromal cells (MSCs) can be harvested from patients, genetically engineered, and subsequently returned to the patient as an implant releasing on a continuous basis therapeutic proteins that interfere with cancer growth and spread. We have already developed and published most of the key components required to develop this novel therapeutic modality, such as vectors, MSCs, and matrices. Also thus far, we have shown significant decrease in tumor progression over time with Interleukin-l2-secreting MSCs in the 4T1 mouse model of breast cancer and ascertained reproducibility of these results.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 27
Get Book Here
Book Description
The plasminogen kringle 5 (K5) domain - which is distinct from angiostatin - possesses potent anti-angiogenic properties on its own which can be exploited in cancer therapy. We have previously shown that K5 suppresses cancer growth in tumor xenograft models, its modulation of inflammation in experimental mice with intact immune systems is unknown. To determine whether K5 possesses immune proinflammatory properties, we investigated the effects of K5 in an immune competent model of breast cancer and observed that tumor rejection is substantially reduced in NOD-SCID and BALB/c nude when compared to wild-type BALB/c mice, suggesting an important role for T-lymphoid cells in the anti-tumor effect of K5. Tumor explant analysis demonstrates that K5 enhances tumor recruitment of CD3+ lymphoid cells, in particular the NKT phenotype. We also observed a significant decrease in tumor-associated microvessel length and density consistent with anti-angiogenic activity. Histological analysis of K5 tumors also revealed a robust neutrophilic infiltrate, which may be explained by the neutrophil chemotactic activity of K5 as well as its ability to promote CD64 upregulation within the CD11b+ adhesive neutrophil population. In sum, our findings confirm that the K5 protein acts as a potent angiostatic agent and possesses a novel proinflammatory role via its ability to recruit tumor-associated neutrophils and NKT-lymphocytes, leading to a potent anti-tumor response.
Author: Nancy Smyth Templeton
Publisher: CRC Press
ISBN: 0824758609
Category : Science
Languages : en
Pages : 894
Get Book Here
Book Description
This reference is completely revised and expanded to reflect the most critical studies, controversies, and technologies impacting the medical field, including probing research on lentivirus, gutless adenovirus, bacterial and baculovirus vectors, retargeted viral vectors, in vivo electroporation, in vitro and in vivo gene detection systems, and all inducible gene expression systems. Scrutinizing every tool, technology, and issue impacting the future of gene and cell research, it is specifically written and organized for laymen, scholars, and specialists from varying backgrounds and disciplines to understand the current status of gene and cell therapy and anticipate future developments in the field.
Author: Darren W. Davis
Publisher: CRC Press
ISBN: 1420004298
Category : Medical
Languages : en
Pages : 878
Get Book Here
Book Description
Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bev
Author: Kirby I. Bland
Publisher: Elsevier Health Sciences
ISBN: 1437711219
Category : Medical
Languages : en
Pages : 1605
Get Book Here
Book Description
The Breast: Comprehensive Management of Benign and Malignant Diseases, 4th Edition, by Kirby I. Bland, MD, and Edward M. Copeland, III, MD, is a surgical reference that offers the most comprehensive, up-to-date resource on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the breast. With its multidisciplinary approach, sweeping updates, new contributors, and authoritative guidance, you’ll have exactly what you need to inspire patient confidence and provide the best possible outcomes. Features multidisciplinary advice from experts in surgery, radiation and medical oncology, pathology, molecular biology, pharmacokinetics, and genetics for a well-rounded perspective to enhance patient outcomes. Includes more than 1,500 figures and tables that offer high quality depictions of surgery and treatment procedures. Offers step-by-step guidance through both text and clinical boxes that makes the material relevant to everyday practice. Provides cross-referencing between chapters, as well as references to carefully selected journal articles, that makes further research easier. Uses a new full-color design to highlight key areas of the text and help you focus on important concepts. Presents updated coverage including an expanded section on pathology...and new chapters on granular cell tumors, targeted therapies, integration of radiotherapy and chemotherapy to keep you current. Includes revised chapters on the psychosocial consequences of breast cancer, lifestyle interventions for breast cancer patients, and patient and family resources that equip you to offer complete and compassionate care. Provides additional information on genetics to keep you up to date with the latest genetic discoveries linked to breast cancer and breast diseases. Features the work of many new contributors who provide the latest and freshest perspectives.
Author: Wilma B. Gustafsson
Publisher: Nova Publishers
ISBN: 9781600219696
Category : Medical
Languages : en
Pages : 332
Get Book Here
Book Description
Gene therapy is an experimental treatment that involves introducing genetic material into a person's cells to fight disease. Gene therapy is being studied in clinical trials for many different types of cancer and for numerous other diseases. This book offers research from around the globe dedicated to this subject.
Author: Khalid Shah
Publisher: Elsevier
ISBN: 0124166652
Category : Science
Languages : en
Pages : 43
Get Book Here
Book Description
With the thorough understanding of stem cell biology and the advent of targeted therapeutics for cancer, stem cell-based therapeutic strategies are being increasingly explored for the treatment of various cancer types. Mesenchymal Stem Cells in Cancer Therapy sheds light on current stem cell based targeted therapies for cancer, by focusing on the application of mesenchymal stem cells (MSC) in various cancers with emphasis on a number of aspects that are critical to the success of future stem cell based therapies for cancer. Sections of this publication are devoted to developing stem cell based therapies for cancer with the main focus on tumoritrophic properties of stem cells, engineering targeted therapeutics, utilization of imaging techniques and the recent combination studies utilizing currently employed therapeutics with stem cells. Mesenchymal Stem Cells in Cancer Therapy informs readers about critical and cutting edge stem cell therapies for cancer and also enables them to appreciate the vast plain of unresolved questions in stem cell research for cancer therapeutics. - Includes biological foundation on key sources of mesenchymal stem cells and the various ways they can be utilized to treat cancer - Provides examples of current MSC based cancer therapies and prospects for the future with insights from the leading lab on cancer cell therapies - Technically advanced topic written for widespread understanding for clinical and research audiences
Author: Phuc Van Pham
Publisher:
ISBN: 9783319220215
Category :
Languages : en
Pages :
Get Book Here
Book Description
This volume thoroughly examines breast cancer stem cells (BCSCs), from basic definitions to techniques for identifying, isolating, culturing, and targeting BCSCs for therapy; there is additional focus on pre-clinical and clinical results. The text begins with a discussion of breast cancer, focusing especially on the limitations of current therapies in its treatment. The subsequent chapters introduce and compare stem cells and cancer stem cells, describe properties and isolation techniques of BCSCs, and examine BCSC-targeting approaches. The text concludes with a discussion of controversy surrounding the BCSC hypothesis and of future research directions. Breast Cancer Stem Cells & Therapy Resistance, part of the SpringerBriefs in Stem Cells series, provides a succinct yet comprehensive overview of BCSCs for advanced students, graduate students and researchers as well as those working with breast cancer or stem cells in a clinical setting.
Author:
Publisher:
ISBN:
Category : Chemistry
Languages : en
Pages : 2540
Get Book Here
Book Description
Author: Tim F. Greten
Publisher: Springer
ISBN: 9783319879116
Category : Medical
Languages : en
Pages : 0
Get Book Here
Book Description
In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients.
